Krystal Biotech, Inc. $KRYS Shares Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 30.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,170 shares of the company’s stock after acquiring an additional 2,850 shares during the quarter. Krystal Biotech comprises about 0.4% of Privium Fund Management B.V.’s investment portfolio, making the stock its 29th biggest holding. Privium Fund Management B.V.’s holdings in Krystal Biotech were worth $2,148,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Edgestream Partners L.P. bought a new stake in Krystal Biotech during the 2nd quarter worth approximately $2,705,000. Voya Investment Management LLC grew its position in shares of Krystal Biotech by 46.7% during the 3rd quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock worth $16,578,000 after buying an additional 29,915 shares during the period. EFG Asset Management North America Corp. grew its holdings in shares of Krystal Biotech by 18.4% in the 3rd quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock valued at $4,784,000 after buying an additional 4,217 shares during the period. State of New Jersey Common Pension Fund D increased its stake in Krystal Biotech by 45.2% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Krystal Biotech in the second quarter valued at about $38,861,000. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently commented on KRYS. Zacks Research raised Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $277.89.

Krystal Biotech Trading Down 0.0%

NASDAQ KRYS opened at $279.24 on Friday. The company has a market cap of $8.10 billion, a P/E ratio of 41.87 and a beta of 0.46. The company has a fifty day simple moving average of $251.19 and a 200 day simple moving average of $196.77. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $295.98.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.